TY - JOUR
T1 - Predictive value of atrial fibrillation during the postradiofrequency ablation blanking period
AU - Calkins, Hugh
AU - Gache, Larry
AU - Frame, Diana
AU - Boo, Lee Ming
AU - Ghaly, Nader
AU - Schilling, Richard
AU - Deering, Thomas
AU - Duytschaever, Mattias
AU - Packer, Douglas L.
N1 - Funding Information:
Funding sources: This work was supported by Biosense Webster , Inc. Disclosures: Dr Calkins reports personal fees from Biosense Webster , Inc., Medtronic, Abbott Medical, and AtriCure . Mr Larry Gache is an employee of and Ms Diana Frame is a consultant to CTI Clinical Trial and Consulting Services, a consultant to Biosense Webster, Inc. Drs Boo and Ghaly are employees of and own stock in Biosense Webster, Inc. Dr Schilling reports grants, personal fees, and non-financial support from Biosense Webster , Inc., Medtronic, Boston Scientific, and Abbott Medical; other from Rhythm AI, outside the submitted work; and has a patent on STAR mapping pending. Dr Deering is a paid consultant to CVRx; and reports institutional research grants from Medtronic, Abbott, and Biosense Webster , Inc., for which he does not receive any personal compensation. Dr Packer reports relevant activities outside the submitted work, including grants and unpaid advisory board with Biosense Webster Inc., Abbott, and Medtronic; consulting work for Biotronik; and grants and unpaid consulting with Boston Scientific and CardioFocus; grants from Endosense, German Heart Foundation , St. Jude Medical, Siemens , Thermedical, Hansen Medical, and CardioInsight; and unpaid consulting or advisory board with Artfix, Johnson & Johnson , Spectrum Dynamics, and Signum Preemptive Healthcare. Dr Duytschaever has reported that he has no relationships relevant to the contents of this paper to disclose.
Funding Information:
Funding sources: This work was supported by Biosense Webster, Inc. Disclosures: Dr Calkins reports personal fees from Biosense Webster, Inc., Medtronic, Abbott Medical, and AtriCure. Mr Larry Gache is an employee of and Ms Diana Frame is a consultant to CTI Clinical Trial and Consulting Services, a consultant to Biosense Webster, Inc. Drs Boo and Ghaly are employees of and own stock in Biosense Webster, Inc. Dr Schilling reports grants, personal fees, and non-financial support from Biosense Webster, Inc., Medtronic, Boston Scientific, and Abbott Medical; other from Rhythm AI, outside the submitted work; and has a patent on STAR mapping pending. Dr Deering is a paid consultant to CVRx; and reports institutional research grants from Medtronic, Abbott, and Biosense Webster, Inc., for which he does not receive any personal compensation. Dr Packer reports relevant activities outside the submitted work, including grants and unpaid advisory board with Biosense Webster Inc., Abbott, and Medtronic; consulting work for Biotronik; and grants and unpaid consulting with Boston Scientific and CardioFocus; grants from Endosense, German Heart Foundation, St. Jude Medical, Siemens, Thermedical, Hansen Medical, and CardioInsight; and unpaid consulting or advisory board with Artfix, Johnson & Johnson, Spectrum Dynamics, and Signum Preemptive Healthcare. Dr Duytschaever has reported that he has no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2020 Heart Rhythm Society
PY - 2021/3
Y1 - 2021/3
N2 - Background: Recurrent arrhythmia following catheter ablation of atrial fibrillation (AF) may present early, during a standard 3-month blanking period. Early recurrence has been correlated to late recurrence, but the degree to which its absence predicts longer-term success has not been quantified. Objective: The purpose of this study was to explore and quantify the relationship between early and late arrhythmia recurrence, specifically the negative predictive value, that is, the degree to which absence of blanking period recurrence predicts absence of late recurrence. Methods: A systematic literature review and meta-analysis were conducted using statistical methods of a diagnostic test accuracy review. Studies of AF ablation using point-by-point radiofrequency, with repeated monitoring of arrhythmia recurrence including asymptomatic recurrence, and with separate data by AF type, were eligible. Results: Nine studies met the prespecified eligibility criteria. For paroxysmal AF, 89% (confidence interval [CI] 82%–94%) of patients free from early recurrence remained free from late recurrence. The estimate for persistent AF was similar (91%; CI 75%–97%). This finding was robust in sensitivity analyses. Patients with early recurrence had a wider range of likely outcomes with longer-term follow-up. Conclusion: Freedom from AF recurrence during the blanking period is highly predictive of longer-term success in catheter ablation. Clinical trials in this area may be able to leverage these findings to more quickly assess the potential utility of new ablation technologies and methods, for example, by using early surrogate measures of success.
AB - Background: Recurrent arrhythmia following catheter ablation of atrial fibrillation (AF) may present early, during a standard 3-month blanking period. Early recurrence has been correlated to late recurrence, but the degree to which its absence predicts longer-term success has not been quantified. Objective: The purpose of this study was to explore and quantify the relationship between early and late arrhythmia recurrence, specifically the negative predictive value, that is, the degree to which absence of blanking period recurrence predicts absence of late recurrence. Methods: A systematic literature review and meta-analysis were conducted using statistical methods of a diagnostic test accuracy review. Studies of AF ablation using point-by-point radiofrequency, with repeated monitoring of arrhythmia recurrence including asymptomatic recurrence, and with separate data by AF type, were eligible. Results: Nine studies met the prespecified eligibility criteria. For paroxysmal AF, 89% (confidence interval [CI] 82%–94%) of patients free from early recurrence remained free from late recurrence. The estimate for persistent AF was similar (91%; CI 75%–97%). This finding was robust in sensitivity analyses. Patients with early recurrence had a wider range of likely outcomes with longer-term follow-up. Conclusion: Freedom from AF recurrence during the blanking period is highly predictive of longer-term success in catheter ablation. Clinical trials in this area may be able to leverage these findings to more quickly assess the potential utility of new ablation technologies and methods, for example, by using early surrogate measures of success.
KW - Atrial fibrillation
KW - Catheter ablation
KW - Predictive value of tests
UR - http://www.scopus.com/inward/record.url?scp=85099623388&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099623388&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2020.11.020
DO - 10.1016/j.hrthm.2020.11.020
M3 - Article
C2 - 33242668
AN - SCOPUS:85099623388
SN - 1547-5271
VL - 18
SP - 366
EP - 373
JO - Heart Rhythm
JF - Heart Rhythm
IS - 3
ER -